SYNLOGIC, INC. Increase (Decrease) in Accounts Receivable
SYNLOGIC, INC. (SYBX) reported Increase (Decrease) in Accounts Receivable of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2023-11-09
- SYNLOGIC, INC. increase (decrease) in accounts receivable for the quarter ending 2021-09-30 was $0.00.
- SYNLOGIC, INC. increase (decrease) in accounts receivable for the quarter ending 2019-03-31 was $2.50M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2022-09-30 | -$1.50M 10-Q · filed 2023-11-09 | $1.50M 10-Q · filed 2022-11-10 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.00M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-11 | |||
| 2019-03-31 | $2.50M 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $2.00M 10-Q · filed 2019-11-12 | |||
| 2017-06-30 | $2.00M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |